Table 2. Clinical Outcomes After Atorvastatin Treatment or Placebo .

	Baseline			6 months
	Atorvastatin	Placebo	P Value	Atorvastatin	Placebo	P Value
6 MWD a	238 ± 124	284 ± 100	0.17	339 ± 155	340 ± 106	0.98
FEV1 (%)	44 ± 25.2	43.5 ± 13.1	0.93	47.6 ± 28.4	48.6 ± 19.3	0.90
FVC (%)	54.7 ± 19.5	64.9 ± 18.4	0.08	62.5 ± 23.3	66.3 ± 17.9	0.58
FEV1/VC	57.4 ± 13.0	54.8 ± 9.9	0.46	55.9 ±15.5	57.4 ± 15.3	0.78
Cardiac output (%)	46.8 ± 9.7	46.6 ± 10.28	0.94	46.6 ± 5.9	46 ± 7.6	0.79
SPAH b	48.5 ± 6.9	49.7 ± 11.4	0.66	42.9 ± 9.3	48.2 ± 14.6	0.19
RSV c	2.47 ± 0.88	2.72 ± 1.25	0.46	2.40 ± 1.02	2.33 ± 0.84	0.82
LDL (mg/dl)	109 ± 33	104 ± 31	0.66	86 ± 21	111 ± 33	0.01

^a 6 Min Walk Distance (meter)

^b Systolic Pulmonary Arterial Hypertension (mmHg)

^c Right Size Ventricle (cm)